Search Result

Results for "

DM

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (1) 5-HT Receptor (8) Acyltransferase (1) ADC Linker (4) ADC Payload (14) Adenosine Receptor (1) Aldose Reductase (2) Amylases (1) Antibiotic (1) Antibody-Drug Conjugates (ADCs) (18) Antibody-Oligonucleotide Conjugates (AOCs) (3) Antifolate (1) Apoptosis (6) Autophagy (3) Bacterial (3) Biochemical Assay Reagents (6) Calcium Channel (2) CCR (2) Cytochrome P450 (2) Dipeptidyl Peptidase (9) DNA Alkylator/Crosslinker (3) DNA/RNA Synthesis (1) Dopamine Receptor (3) Drug Derivative (1) Drug Metabolite (8) Drug-Linker Conjugates for ADC (27) EGFR (3) Endogenous Metabolite (5) Estrogen Receptor/ERR (2) FGFR (1) Fluorescent Dye (1) Free Fatty Acid Receptor (3) GABA Receptor (2) GCGR (5) GLP Receptor (5) Glucocorticoid Receptor (1) GLUT (1) Glycosidase (10) GPR109A (2) GPR119 (2) HIF/HIF Prolyl-Hydroxylase (1) Histone Methyltransferase (1) HMG-CoA Reductase (HMGCR) (1) iGluR (5) IKK (3) Insulin Receptor (1) Interleukin Related (4) Isotope-Labeled Compounds (14) Keap1-Nrf2 (1) Ketohexokinase (1) LRRK2 (3) mGluR (2) Microtubule/Tubulin (21) Mineralocorticoid Receptor (1) nAChR (2) NF-κB (3) Organoid (3) P-glycoprotein (5) PARP (4) Phosphatase (2) Phosphodiesterase (PDE) (2) PI3K (2) PKC (2) PKD (3) Potassium Channel (1) PPAR (1) Quinone Reductase (1) Reactive Oxygen Species (ROS) (1) Reference Standards (9) SGLT (8) Small Interfering RNA (siRNA) (2) Sodium Channel (2) Somatostatin Receptor (3) Target Protein Ligand-Linker Conjugates (2) TGF-beta/Smad (1) TGF-β Receptor (4) TNF Receptor (3) Topoisomerase (1) Transferrin Receptor (2) Vasopressin Receptor (1) VDAC (1) Wnt (2) β-catenin (3)
By Research Areas:	Cancer (93) Cardiovascular Disease (10) Endocrinology (6) Infection (2) Inflammation/Immunology (14) Metabolic Disease (71) Neurological Disease (12)
Click Chemistry:	ADC Synthesis (2) DBCO (2)
Oligonucleotides:	Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) Antisense Oligonucleotides (3) siRNAs (2)

200

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-101070

SMCC-DM1 10+ Cited Publications DM1-SMCC	Drug-Linker Conjugates for ADC	Cancer
SMCC-DM1 (DM1-SMCC) is a agent-linker conjugate composed of a potent microtubule-disrupting agent DM1 and a linker SMCC to make antibody agent conjugate (ADC) .

HY-130080

DM3 Maytansinoid DM3	ADC Payload Microtubule/Tubulin	Cancer
DM3 (Maytansinoid DM3), a Maytansine (HY-13674) analog bearing disulfide or thiol groups, and is a tubulin inhibitor. DM3 a cytotoxic moiety of antibody-drug conjugates (ADCs) .

HY-100128

DM1-SMe	Microtubule/Tubulin ADC Payload	Cancer
DM1-SMe is an unconjugated form of the Maytansinoid in IMGN901. DM1-SMe is the microtubule inhibitor and can be used as the ADC cytotoxin .

HY-12454S

DM4-d6	Isotope-Labeled Compounds Microtubule/Tubulin ADC Payload	Cancer
DM4-d₆ is deuterium labeled DM4. DM4 is is an antitubulin agent that inhibit cell division. DM4 can be used in the preparation of antibody agent conjugate.

HY-130082

DM4-SMe	ADC Payload Microtubule/Tubulin	Cancer
DM4-SMe is a metabolite of antibody-maytansin conjugates (AMCs) and a tubulin inhibitor, and also a cytotoxic moiety of antibody-drug conjugates (ADCs), which can be linked to antibody through disulfide bond or stable thioether bond. DM4-SMe inhibits KB cells with an IC₅₀ of 0.026 nM. DM4-SMe is a highly toxic metabolite that can be oxidized and detoxified by human liver microsomes .

HY-126494

DM4-SMCC	Drug-Linker Conjugates for ADC	Cancer
DM4-SMCC is a agent-linker conjugate for ADC with antitumor activity by using DM4 (an antitubulin agent), linked via the non-cleavable SMCC linker .

HY-48703

DM1 Impurity	Microtubule/Tubulin	Cancer
DM1 Impurity is the impurity of Mertansine (DM1) (HY-19792) .

HY-165423

DM-4111	Vasopressin Receptor Drug Metabolite	Cardiovascular Disease
DM-4111, one of the major monohydroxyl metabolites of Tolvaptan (HY-17000), is a potent vasopressin V₂ receptor inhibitor. DM-4111 inhibits water reabsorption in the renal tubules, thereby promoting the excretion of electrolyte-free water. DM-4111 is promising for research of cardiovascular diseases .

HY-W702908

DM-4107	P-glycoprotein	Metabolic Disease
DM-4107 is a major metabolite of Tolvaptan (HY-17000) that is metabolized primarily by the CYP3A4 enzyme in the liver. DM-4107 inhibits the ability of human liver transporters NTCP, BSEP, MRP3, MRP4 (IC₅₀ values are 95.6, 119, 61.2, 37.9 μM, respectively) and bile acid transport in SCHH cells. DM-4107 can be used in the study of autosomal dominant polycystic kidney disease (ADPKD) .

HY-W702907

DM-4103	P-glycoprotein	Metabolic Disease
DM-4103 is a major metabolite of Tolvaptan (HY-17000) that is metabolized primarily by the CYP3A4 enzyme in the liver. DM-4103 inhibits the ability of human liver transporters NTCP, BSEP, MRP2, MRP3, MRP4 (IC₅₀ values are 16.3, 4.15, 51.0, 44.6, 4.26 μM, respectively) and bile acid transport in SCHH cells. DM-4103 can be used in the study of autosomal dominant polycystic kidney disease (ADPKD) .

HY-126789

DM-Nitrophen	Biochemical Assay Reagents	Others
DM-Nitrophen is a Ca ²⁺ cage. DM-Nitrophen releases Ca ²⁺ when cleaved upon illumination with near-ultraviolet light .

HY-130081

DM3-SMe	ADC Payload Microtubule/Tubulin	Cancer
DM3-SMe is a maytansine derivative and a tubulin inhibitor, and is a cytotoxic moiety of antibody-drug conjugates (ADCs), which can be linked to antibody through disulfide bond or stable thioether bond. DM3-SMe shows highly cytotoxic activity in vitro with an IC₅₀ of 0.0011 nM .

HY-126789A

DM-Nitrophen tertasodium	Biochemical Assay Reagents	Others
DM-Nitrophen tertasodium is a Ca ²⁺ cage. DM-Nitrophen releases Ca ²⁺ when cleaved upon illumination with near-ultraviolet light . DM-Nitrophen tertasodium can be used for study of Ca ²⁺ signaling .

HY-12454

DM4 4 Publications Verification Ravtansine	Microtubule/Tubulin ADC Payload	Cancer
DM4 is is an antitubulin agent that inhibit cell division. DM4 can be used in the preparation of antibody agent conjugate.

HY-171126

DM21-L-G	Drug-Linker Conjugates for ADC	Others
DM21-L-G is a Drug-Linker Conjugates that can be used to synthesize ADC molecules .

HY-139441

DM21	Drug-Linker Conjugates for ADC Microtubule/Tubulin	Cancer
DM21 is a next-generation linker-payload that combines a maytansinoid microtubule-disrupting payload with a stable tripeptide linker. DM21 is conjugated with a humanized antibody against ADAM9 to obtain IMGC936 .

HY-126493

DM4-SPDP	Drug-Linker Conjugates for ADC Microtubule/Tubulin	Cancer
DM4-SPDP is a agent-linker conjugate composed of a potent antitubulin agent DM4 and a linker SMCC to make antibody agent conjugate . SPDP is a short-chain crosslinker for amine-to-sulfhydryl conjugation via NHS-ester and pyridyldithiol reactive groups that form cleavable (reducible) disulfide bonds with cysteine sulfhydryls .

HY-125931

Unifiram DM232	iGluR	Neurological Disease
Unifiram (DM232) is acts as a potent cognition enhancer through the activation of the AMPA-mediated neurotransmission system. Unifiram (DM232) has the potential for amnesia prevention and neurodegenerative disorder research .

HY-136261

DM1-PEG4-DBCO	Drug-Linker Conjugates for ADC	Cancer
DM1-(PEG)4-DBCO is a agent-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody agent conjugate (ADC). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. DM1-PEG4-DBCO is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-131246

DM-01	Histone Methyltransferase	Cancer
DM-01 is a powerful and selective EZH2 inhibitor for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and SNF5/INI-1/SMARCB1 genetically defined solid tumors .

HY-W190944

DM1-MCC-PEG3-Biotin	Drug-Linker Conjugates for ADC	Cancer
DM1-MCC-PEG3-Biotin is a drug-linker conjugate for ADC.

HY-143987S

DM51 impurity 1-d9	Drug Metabolite Isotope-Labeled Compounds	Others
DM51 impurity 1-d₉ is the deuterium labeled DM51 impurity 1 .

HY-143986S

DM50 impurity 1-d9	Drug Metabolite Isotope-Labeled Compounds	Others
DM50 impurity 1-d₉ is the deuterium labeled DM50 impurity 1 .

HY-143986S1

DM50 impurity 1-d9-1	Drug Metabolite Isotope-Labeled Compounds	Others
DM50 impurity 1-d₉-1 is the deuterium labeled DM50 impurity 1 .

HY-112068

DM-NOFD	HIF/HIF Prolyl-Hydroxylase	Cancer
DM-NOFD is a cell penetrant, prodrug of NOFD a potent and selective inhibitor of an asparaginyl hydroxylase FIH (factor-inhibiting HIF) .

HY-N14732

Demycarosyl platenomycin DM-PLM	Antibiotic Bacterial	Infection
Demycarosylplatenomycin (DM-PLM) is an antibiotic with weak activity against Gram-positive bacteria .

HY-17550

Sunifiram DM-235	iGluR	Neurological Disease
Sunifiram (DM-235) is an ampakine-like compound and an agonist of AMPA receptor with oral activity. Sunifiram can increase the release of acetylcholine in the rat cerebral cortex and exhibits potent cognitive enhancement effects with better nootropic activity compared to piracetam (HY-B0585). Sunifiram is promising for research in neurodegenerative diseases such as mild cognitive impairment (MCI) and Alzheimer's disease (AD) .

HY-19792

Mertansine 20+ Cited Publications DM1; Maytansinoid DM1	Microtubule/Tubulin ADC Payload	Cancer
Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC) .

HY-12071G

LDN193189 DM-3189	TGF-β Receptor	Cancer
LDN193189 (DM-3189) (GMP) is LDN193189 (HY-12071) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. LDN193189 is selective BMP type I receptor inhibitor .

HY-143987

DM51 impurity 1	Others	Others
DM51 impurity 1 is a natural product related to Maytansine (HY-13674) .

HY-124348

DM-PIT-1 3,5-Dimethyl PIT-1	PI3K	Cancer
DM-PIT-1 is a PIP3/PH (phosphatidylinositol-3,4,5-triphosphate/Pleckstrin) interaction inhibitor. DM-PIT-1 decreases he expression of P-Akt, P-GSK-3-β, P-p70S6K, P-S6, P-4E-BP1. DM-PIT-1 induces apoptosis and shows anticancer activity. DM-PIT-1 has the potential for the research of ovarian cancer .

HY-U00194

Vebufloxacin Flumenique; OPC7241; DM8966	Bacterial	Infection
Vebufloxacin (Flumenique; OPC7241; DM8966) exhibits potent antibacterial activity against gram-positive and -negative bacteria.

HY-133152

Brexpiprazole S-oxide DM-3411	5-HT Receptor Dopamine Receptor	Neurological Disease
Brexpiprazole S-oxide (DM-3411) is a main metabolite of Brexpiprazole and is metabolized by cytochrome P450 3A4 (CYP3A4). Brexpiprazole is an atypical antipsychotic agent and a partial agonist of human 5-HT_1A and dopamine receptor with K_is of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT_2A receptor antagonist with a K_i of 0.47 nM .

HY-17550R

Sunifiram (Standard) DM-235 (Standard)	Reference Standards iGluR	Neurological Disease
Sunifiram (Standard) is the analytical standard of Sunifiram. This product is intended for research and analytical applications. Sunifiram (DM-235) is an ampakine-like compound and an agonist of AMPA receptor with oral activity. Sunifiram can increase the release of acetylcholine in the rat cerebral cortex and exhibits potent cognitive enhancement effects with better nootropic activity compared to piracetam (HY-B0585). Sunifiram is promising for research in neurodegenerative diseases such as mild cognitive impairment (MCI) and Alzheimer's disease (AD) .

HY-153043

DM-CO-(CH2)5-SMe	Drug Metabolite	Cancer
DM-CO-(CH2)5-SMe is an anticancer agent derived from antibody-drug conjugates (ADC) metabolite with cytotoxicity to H1703, H1975, COLO704 and Colo720E cells .

HY-133152S

Brexpiprazole S-oxide-d8 DM-3411 d₈	Isotope-Labeled Compounds 5-HT Receptor Dopamine Receptor	Neurological Disease
Brexpiprazole S-oxide-d₈ (DM-3411 D₈) is a deuterium labeled Brexpiprazole S-oxide (HY-133152). Brexpiprazole S-oxide is a main metabolite of Brexpiprazole and is metabolized by cytochrome P450 3A4 (CYP3A4). Brexpiprazole is an atypical antipsychotic agent and a partial agonist of human 5-HT1A and dopamine receptor with K_is of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a Ki of 0.47 nM .

HY-137234

DM-β-CD 2,6-Di-O-methyl-β-cyclodextrin	Biochemical Assay Reagents	Others
DM-β-CD (2,6-Di-O-methyl-β-cyclodextrin) is a cyclic molecule consisting of seven glucose units modified with two methyl groups at the 2- and 6-positions. It is usually used as a solubilizer and carrier for poorly soluble drugs in pharmaceutical preparations. Furthermore, it has applications in analytical chemistry, food science, and environmental remediation due to its ability to form clathrates with various guest molecules, such as aromatic compounds, pesticides, and heavy metals.

HY-12071B

LDN-193189 dihydrochloride Maximum Cited Publications 75 Publications Verification DM-3189 dihydrochloride	TGF-β Receptor Organoid	Cancer
LDN-193189 (dihydrochloride) is a potent selective BMP type I receptor (BMP I) inhibitor. LDN-193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC₅₀ values of 5 nM and 30 nM, respectively. LDN-193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva .

HY-12071C

LDN193189 hydrochloride 60+ Cited Publications DM-3189 hydrochloride	Biochemical Assay Reagents	Others
LDN193189 (hydrochloride) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

HY-12071

LDN193189 Maximum Cited Publications 75 Publications Verification DM-3189	Organoid TGF-β Receptor	Cancer
LDN193189 is a potent selective BMP type I receptor (BMP I) inhibitor. LDN-193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC₅₀ values of 5 nM and 30 nM, respectively. LDN-193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva .

HY-B0340

Nefiracetam DM9384; DZL-221	nAChR iGluR mGluR PKC GABA Receptor Calcium Channel	Neurological Disease
Nefiracetam is a cognition-enhancing agent. Nefiracetam is an activator of nAChR, N-methyl-D-aspartate receptor (NMDAR), mGluR5, PKC, gamma-aminobutyric acid (GABA), and N/L-type Ca ²⁺ channels. Nefiracetam promotes neuroplasticity and enhances neuroprotection. Nefiracetam can be used in Alzheimer's disease, epilepsy, and cerebral ischemia research .

HY-113575

Dehydroaripiprazole hydrochloride 1 Publications Verification OPC-14857 hydrochloride; DM-14857 hydrochloride	5-HT Receptor	Neurological Disease
Dehydroaripiprazole (OPC-14857) hydrochloride is an active metabolite of Aripiprazole. Aripiprazole is an antipsychotic agent and is metabolized by CYP3A4 and CYP2D6 forming mainly Dehydroaripiprazole hydrochloride. Dehydroaripiprazole hydrochloride has with antipsychotic activity equivalent to Aripiprazole .

HY-100665

Dehydroaripiprazole 1 Publications Verification OPC-14857; DM-14857	5-HT Receptor Dopamine Receptor	Neurological Disease
Dehydroaripiprazole (OPC-14857) is an active metabolite of Aripiprazole (HY-14546) and dopamine D₂/D₃ receptor partial agonist. Dehydroaripiprazole also has certain affinity for serotonin 5-HT₁A, 5-HT₂A and 5-HT₂B receptors. Dehydroaripiprazole has antipsychotic activity equivalent to Aripiprazole .

HY-12071A

LDN193189 Tetrahydrochloride Maximum Cited Publications 75 Publications Verification DM-3189 Tetrahydrochloride	Organoid TGF-β Receptor	Cancer
LDN193189 Tetrahydrochloride is a selective BMP type I receptor inhibitor, which efficiently inhibits ALK2 and ALK3 (IC₅₀=5 nM and 30 nM, respectively), with weaker effects on ALK4, ALK5 and ALK7 (IC₅₀≥500 nM) .

HY-RS17187

Dmpk Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Dmpk Mouse Pre-designed siRNA Set A contains three designed siRNAs for Dmpk gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Dmpk Mouse Pre-designed siRNA Set A Dmpk Mouse Pre-designed siRNA Set A

HY-100665R

Dehydroaripiprazole (Standard) OPC-14857 (Standard); DM-14857 (Standard)	Reference Standards 5-HT Receptor	Neurological Disease
Dehydroaripiprazole (Standard) is the analytical standard of Dehydroaripiprazole. This product is intended for research and analytical applications. Dehydroaripiprazole (OPC-14857) is an active metabolite of Aripiprazole (HY-14546) and dopamine D₂/D₃ receptor partial agonist. Dehydroaripiprazole also has certain affinity for serotonin 5-HT₁A, 5-HT₂A and 5-HT₂B receptors. Dehydroaripiprazole has antipsychotic activity equivalent to Aripiprazole .

HY-B0340R

Nefiracetam (Standard) DM9384 (Standard); DZL-221 (Standard)	Reference Standards nAChR iGluR mGluR PKC GABA Receptor Calcium Channel	Neurological Disease
Nefiracetam (Standard) is a cognition-enhancing agent. Nefiracetam is an activator of nAChR, N-methyl-D-aspartate receptor (NMDAR), mGluR5, PKC, gamma-aminobutyric acid (GABA), and N/L-type Ca ²⁺ channels. Nefiracetam promotes neuroplasticity and enhances neuroprotection. Nefiracetam can be used in Alzheimer's disease, epilepsy, and cerebral ischemia research .

HY-RS03827

DMPK Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
DMPK Human Pre-designed siRNA Set A contains three designed siRNAs for DMPK gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

DMPK Human Pre-designed siRNA Set A DMPK Human Pre-designed siRNA Set A

HY-100665S

Dehydroaripiprazole-d8 OPC-14857-d₈; DM-14857-d₈	Isotope-Labeled Compounds 5-HT Receptor	Neurological Disease
Dehydroaripiprazole-d₈ is deuterium labeled Dehydroaripiprazole. Dehydroaripiprazole (OPC-14857) is an active metabolite of Aripiprazole. Aripiprazole is an antipsychotic agent and is metabolized by CYP3A4 and CYP2D6 forming mainly Dehydroaripiprazole. Dehydroaripiprazole has with antipsychotic activity equivalent to Aripiprazole .

HY-157465

MA-PEG4-VC-PAB-DMEA-duocarmycin DM	Drug-Linker Conjugates for ADC	Cancer
MA-PEG4-VC-PAB-DMEA-duocarmycin DM is a drug-linker conjugate for ADC by using the DNA minor-groove alkylator Duocarmycin DM (HY-130978), linked via MA-PEG4-vc-PAB-DMEA (HY-126668).

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-120140

Ganoderic acid DM 1 Publications Verification	Triterpenes Classification of Application Fields Terpenoids Polyporaceae Source classification Metabolic Disease Ganoderma lucidum (Leyss. Ex Fr.) Karst. Plants Inflammation/Immunology Disease Research Fields	Apoptosis PI3K
Ganoderic acid DM, a natural triterpenoid isolated from Ganoderma lucidum, induces DNA damage, G1 cell cycle arrest and apoptosis in human breast cancer cells. Ganoderic acid DM as a specific inhibitor of osteoclastogenesis .

HY-N0171B

Beta-Sitosterol (purity>75%) β-Sitosterol (purity>75%); 22,23-Dihydrostigmasterol (purity>75%)	Cardiovascular Disease other families Classification of Application Fields Source classification Plants Inflammation/Immunology Disease Research Fields Steroids	Apoptosis
Beta-Sitosterol (purity>75%) is a phytosterol with oral activity. Beta-Sitosterol (purity>75%) interferes with a variety of cell signaling pathways, including the cell cycle, apoptosis and cell proliferation. Beta-Sitosterol (purity>75%) has anti-inflammatory, antioxidant, and antitumor activities .

HY-W004874

2,6-Dimethylhydroquinone M-Xylohydroquinone	Classification of Application Fields Source classification Phenols Polyphenols Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
2,6-Dimethylhydroquinone is a key metabolic intermediate for the Mycobacterium strain DM1 during the degradation of 2,6-dimethylphenol (2,6-xylenol). 2,6-Dimethylhydroquinone can serve as an indicator for early failures in biological treatment systems .

HY-B1021

Vincamine 1 Publications Verification	Apocynaceae Cardiovascular Disease Alkaloids Classification of Application Fields Source classification Plants Disease Research Fields Indole Alkaloids Catharanthus roseus (L.) G. Don	Free Fatty Acid Receptor
Vincamine is a monoterpenoid indole alkaloid extracted from the Madagascar periwinkle. Vincamine is a peripheral vasodilator and exerts a selective vasoregulator action on the brain microcapilar circulation . Vincamine is a GPR40 agonist and acts as a β-cell protector by ameliorating β-cell dysfunction and promoting glucose-stimulated insulin secretion (GSIS). Vincamine improves glucose homeostasis in vivo, and has the potential for the type 2 diabetes mellitus (T2DM) research .

HY-N14732

Demycarosyl platenomycin DM-PLM	Microorganisms Antibiotics Source classification Other Antibiotics	Antibiotic Bacterial
Demycarosylplatenomycin (DM-PLM) is an antibiotic with weak activity against Gram-positive bacteria .

HY-107259

23S-Hydroxyl-11,15-dioxo-ganoderic acid DM 23S-Hydroxy-3,7,11,15-tetraoxo-lanost-8,24E-diene-26-oic	Triterpenes Classification of Application Fields Terpenoids Source classification Polyporaceae Other Diseases Plants Disease Research Fields	Others
23S-Hydroxyl-11,15-dioxo-ganoderic acid DM is a compound isolated from the fruit bodies of Ganoderma lucidum .

HY-N11919

Anticancer agent 149	Source classification Phenols Polyphenols Plants Dioscorea membranacea Pierre ex Prain & Burkill Dioscoreaceae	Others
Anticancer agent 149 (compound 3) is an anticancer agent isolated from the rhizome of Dioscorea dioscorea (DM). Anticancer agent 149 exhibits selective cytotoxic activity against MCF-7 cells (IC₅₀=31.41 μM) .

HY-N8491

Dihydrocarveol	Cymbopogon martini Terpenoids Gramineae Source classification Diterpenoids Plants	Others
Dihydrocarveol is an anticancer agent. Dihydrocarveol shows inhibitory activity against human colon adenocarcinoma cells (HCT-116, HT-29, COLO320DM) with an IC₅₀ value of 28.31 μM in HCT-116 cells. Dihydrocarveol is promising for research of colon cancer .

HY-W004874R

2,6-Dimethylhydroquinone (Standard)	Source classification Phenols Polyphenols Endogenous metabolite	Reference Standards Endogenous Metabolite
2,6-Dimethylhydroquinone (Standard) is an analytical standard for 2,6-Dimethylhydroquinone (HY-W004874). This product is intended for research and analytical applications. 2,6-Dimethylhydroquinone is a key metabolic intermediate in the degradation of 2,6-xylenol by Mycobacterium strain DM1. 2,6-Dimethylhydroquinone can be used as an early indicator of failure in biological treatment systems.

HY-B1021R

Vincamine (Standard)	Apocynaceae Alkaloids Source classification Plants Indole Alkaloids Catharanthus roseus (L.) G. Don	Reference Standards Free Fatty Acid Receptor
Vincamine (Standard) is the analytical standard of Vincamine. This product is intended for research and analytical applications. Vincamine is a monoterpenoid indole alkaloid extracted from the Madagascar periwinkle. Vincamine is a peripheral vasodilator and exerts a selective vasoregulator action on the brain microcapilar circulation . Vincamine is a GPR40 agonist and acts as a β-cell protector by ameliorating β-cell dysfunction and promoting glucose-stimulated insulin secretion (GSIS). Vincamine improves glucose homeostasis in vivo, and has the potential for the type 2 diabetes mellitus (T2DM) research .

HY-N0500

Mogroside III	Triterpenes Classification of Application Fields Terpenoids Source classification Cucurbitaceae Metabolic Disease Siraitia grosvenorii (Swingle) C. Jeffrey ex Lu et Z. Y. Zhang Plants Disease Research Fields Sweeteners Food Research	Glycosidase Autophagy
Mogroside III is a triterpenoid glycoside. Mogroside III exhibits maltase inhibitory effect with an IC₅₀ value of 1.6 mM. Mogroside III enhances oocyte developmental potential by promoting autophagy in cumulus cells. Mogroside III, as the active ingredient of the low-polarity glycoside component (L-SGgly), L-SGgly can increase serum GLP-1 levels, improve insulin resistance, and reduce IL-6 levels, and has hypoglycemic, lipid-regulating and anti-inflammatory effects. Mogroside III can be used for the studies of type 2 diabetes mellitus (T2DM) and assisted reproductive technology .

HY-155156

PF-07238025	Cardiovascular Disease Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite
PF-07238025 is a BCKDC kinase (BDK) inhibitor (EC₅₀=19 nM). PF-07238025 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07238025 improved cardiometabolic endpoints and improves glucose tolerance in mice .

HY-155157

PF-07247685	Cardiovascular Disease Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite
PF-07247685 is a BCKDC kinase (BDK) inhibitor (EC₅₀=2.2 nM). PF-07247685 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07247685 improved cardiometabolic endpoints and improves glucose tolerance in mice .

Cat. No.	Product Name	Chemical Structure

HY-12454S

DM4-d6
DM4-d₆ is deuterium labeled DM4. DM4 is is an antitubulin agent that inhibit cell division. DM4 can be used in the preparation of antibody agent conjugate.

HY-133152S

Brexpiprazole S-oxide-d8

Brexpiprazole S-oxide-d₈ (DM-3411 D₈) is a deuterium labeled Brexpiprazole S-oxide (HY-133152). Brexpiprazole S-oxide is a main metabolite of Brexpiprazole and is metabolized by cytochrome P450 3A4 (CYP3A4). Brexpiprazole is an atypical antipsychotic agent and a partial agonist of human 5-HT1A and dopamine receptor with K_is of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a Ki of 0.47 nM .

HY-143987S

DM51 impurity 1-d9
DM51 impurity 1-d₉ is the deuterium labeled DM51 impurity 1 .

HY-143986S

DM50 impurity 1-d9
DM50 impurity 1-d₉ is the deuterium labeled DM50 impurity 1 .

HY-143986S1

DM50 impurity 1-d9-1
DM50 impurity 1-d₉-1 is the deuterium labeled DM50 impurity 1 .

HY-100665S

Dehydroaripiprazole-d8
Dehydroaripiprazole-d₈ is deuterium labeled Dehydroaripiprazole. Dehydroaripiprazole (OPC-14857) is an active metabolite of Aripiprazole. Aripiprazole is an antipsychotic agent and is metabolized by CYP3A4 and CYP2D6 forming mainly Dehydroaripiprazole. Dehydroaripiprazole has with antipsychotic activity equivalent to Aripiprazole .

HY-143985S

Maytansinoid DM4 impurity 5-d6
Maytansinoid DM4 impurity 5-d₆ is the deuterium labeled Maytansinoid DM4 impurity 5 .

HY-143992S

Maytansinoid DM4 impurity 2-d6
Maytansinoid DM4 impurity 2-d₆ is the deuterium labeled Maytansinoid DM4 impurity 2 .

HY-143993S

Maytansinoid DM4 impurity 3-d6
Maytansinoid DM4 impurity 3-d₆ is the deuterium labeled Maytansinoid DM4 impurity 3 .

HY-14928S1

Lobeglitazone-d4
Lobeglitazone-d₄ is deuterium labeled Lobeglitazone. Lobeglitazone is a new type of thiazolidinedione. Lobeglitazone can be used to prevent type 2 diabetes mellitus (T2DM) .

HY-15408S

Trelagliptin-13C,d3
Trelagliptin-13C,d3 is a deuterated labeled Trelagliptin . Trelagliptin (SYR-472) is a potent, orally active and highly selective DPP-4 inhibitor with an IC₅₀ of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM) .

HY-10450S5

Dapagliflozin-13C6-1
Dapagliflozin- ¹³C₆-1 is ¹³C labeled Dapagliflozin. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin induces HIF1 expression and attenuates renal IR injury .

HY-10450S3

Dapagliflozin-13C6
Dapagliflozin- ¹³C₆ (BMS-512148- ¹³C₆) is ¹³C labeled Dapagliflozin. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin induces HIF1 expression and attenuates renal IR injury .

HY-10450S2

Dapagliflozin-d4
Dapagliflozin-d₄ (BMS-512148-d₄) is deuterium labeled Dapagliflozin. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin induces HIF1 expression and attenuates renal IR injury .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks